ARCHIVES

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

This article is from The Cancer Letter archive.

Vol. 17 No. 36 | September 20, 1991

Download PDF Visit The Full Archive

Related Articles

FDA Guidance for Public Comment at Advisory Committee Meetings

December 10, 2010

In Brief: Final appropriations for NCI Still Probably $875 Million; US-USR Drug Book Available

July 1, 1977

Atrix, Sanofi In Marketing Deal For Leuprogel Products.

January 26, 2001

PRI Purchased By DynCorp; NCI Is Assured No Changes Will Be Made At Frederick

April 13, 1990

FDA Concerned About Data-Dredging In Drug-Diagnostic Applications

January 30, 2009

Cooperative Groups Fight Back: Members Seek Move To Multidisciplinary Approach, More Funds

May 30, 1975